Eric Sachetta Purchases 10,925 Shares of Sensus Healthcare (NASDAQ:SRTS) Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Eric Sachetta purchased 10,925 shares of the business’s stock in a transaction dated Thursday, August 27th. The stock was purchased at an average price of $3.18 per share, for a total transaction of $34,741.50. Following the completion of the acquisition, the director owned 229,943 shares of the company’s stock, valued at approximately $731,218.74. This represents a 4.99% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Eric Sachetta also recently made the following trade(s):

• On Wednesday, August 26th, Eric Sachetta acquired 9,708 shares of Sensus Healthcare stock. The shares were purchased at an average price of $3.29 per share, with a total value of $31,939.32.
• On Monday, August 24th, Eric Sachetta bought 34,697 shares of Sensus Healthcare stock. The stock was purchased at an average cost of $3.25 per share, for a total transaction of $112,765.25.

Sensus Healthcare Stock Performance

NASDAQ SRTS opened at $3.52 on Friday. The stock has a market capitalization of $57.95 million, a price-to-earnings ratio of -3.74 and a beta of 1.10. The stock’s 50 day moving average price is $3.05 and its two-hundred day moving average price is $3.52. Sensus Healthcare, Inc. has a 52 week low of $2.66 and a 52 week high of $5.49.

Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.The firm had revenue of $2.29 million for the quarter, compared to analyst estimates of $4.60 million.

Analysts Set New Price Targets

SRTS has been the topic of several analyst reports. Wall Street Zen cut shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Alliance Global Partners reaffirmed a “buy” rating on shares of Sensus Healthcare in a research report on Monday, August 17th. Lake Street Capital dropped their target price on Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Weiss Ratings cut Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Finally, Citigroup restated a “buy” rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Sensus Healthcare has a consensus rating of “Moderate Buy” and an average target price of $5.83.

Hedge Funds Weigh In On Sensus Healthcare

A number of large investors have recently made changes to their positions in SRTS. Geode Capital Management LLC increased its position in Sensus Healthcare by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 153,917 shares of the company’s stock worth $730,000 after buying an additional 3,766 shares during the period. Sachetta LLC grew its stake in shares of Sensus Healthcare by 6.8% in the fourth quarter. Sachetta LLC now owns 148,508 shares of the company’s stock valued at $591,000 after acquiring an additional 9,500 shares in the last quarter. Pacific Ridge Capital Partners LLC grew its stake in shares of Sensus Healthcare by 21.8% in the fourth quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock valued at $2,781,000 after acquiring an additional 125,245 shares in the last quarter. Jane Street Group LLC bought a new position in Sensus Healthcare during the fourth quarter worth about $79,000. Finally, State Street Corp raised its stake in Sensus Healthcare by 5.2% in the 4th quarter. State Street Corp now owns 69,252 shares of the company’s stock worth $276,000 after purchasing an additional 3,400 shares in the last quarter. Institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.